1. B domain of FVIII is necessary for the clotting activity.
a) True
b) False
b
2. Which of the following are a successful acute and prophylactic protein bypassing agent for haemophilia with inhibitors?
a) Recombinant FVIa
b) Recombinant FVa
c) Recombinant FVIIIa
d) Recombinant FVIIa
d
3. Which of the following catalyzes the conversion of prothrombin to thrombin?
a) Platelets
b) Fibrin
c) Pectinase
d) Thromboplastin
d
4. Elimination of disulfide bond between which two amino acid residues within the A3 domain increases FVIII secretion by 2-fold?
a) C1414 and C1456
b) C1123 and C1158
c) C1785 and C1798
d) C1899 and C1903
d
5. The interaction between FVIII and the Endoplasmic Reticulum (ER) chaperone BiP enhances FVIII secretion.
a) True
b) False
b
6. Protein-engineered bypassing agents have the potential to treat bleeding in haemophilia patients with inhibitors.
a) False
b) True
b
7. Which of the following factors require LMAN1-facilitated transport from the ER to the Golgi?
a) FV and FVI
b) FVII and FVI
c) FVI and FVIII
d) FVIII and FV
d
8. Which of the following enzyme cleaves fibrinogen into fibrin which polymerizes and crosslinks (using factor VIII) into a blood clot?
a) Pepsin
b) Lipase
c) Furin
d) Thrombin
d
9. Furin Cleavage is necessary for FVIII biological functions.
a) True
b) False
b
10. Which of the following can inactivate the activated FVIII?
a) Inactivated protein B
b) Activated protein B
c) Inactivated protein C
d) Activated protein C
d
11. Small changes in the amino acid sequence of proteins can have a profound effect on their immunogenicity.
a) False
b) True
b
12. Removing which of the following enzyme cleavage site impedes the A2 dissociation?
a) Rennin
b) Pepsin
c) Furin
d) Thrombin
d
13. The potency of gene therapy vectors can be enhanced by using bioengineered extended half-life (EHL) FVIII or FIX fusion proteins as transgenes.
a) False
b) True
b
14. How many alternatively spliced transcripts are produced by factor VIII gene?
a) Five
b) Seven
c) Three
d) Two
d
15. APC inactivates FVIIIa by proteolytic cleavage at which of the following sites?
a) R313 and/or R512
b) R454 and/or R565
c) R234 and/or R554
d) R336 and/or R562
d
Sanfoundry Global Education & Learning Series – Protein Engineering.
To practice all exam questions on Protein Engineering,  here is complete set of 1000+ Multiple Choice Questions and Answers.
Participate in the Sanfoundry Certification contest to get free Certificate of Merit. Join our social networks below and stay updated with latest contests, videos, internships and jobs!
Telegram | Youtube | LinkedIn | Instagram | Facebook | Twitter | Pinterest
Youtube | LinkedIn | Instagram | Facebook | Twitter | Pinterest
« Prev - Protein Engineering Questions and Answers – Applications – Engineering Blood Clotting Factor VIII – 1» Next - Protein Engineering Questions and Answers – Applications – Vaccine Development 
